Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CHRS Stock Forecast 2025-2026
$0.75
Current Price
$93.91M
Market Cap
Buy 4
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to CHRS Price Targets
+838.3%
To High Target of $7.00
+704.3%
To Median Target of $6.00
+40.8%
To Low Target of $1.05
CHRS Price Momentum
-1.3%
1 Week Change
-9.6%
1 Month Change
-40.9%
1 Year Change
-45.7%
Year-to-Date Change
-69.3%
From 52W High of $2.43
+13.0%
From 52W Low of $0.66
📊 TOP ANALYST CALLS
Did CHRS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Coherus is one of their latest high-conviction picks.
Latest CHRS Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, CHRS has a bullish consensus with a median price target of $6.00 (ranging from $1.05 to $7.00). Currently trading at $0.75, the median forecast implies a 704.3% upside. This outlook is supported by 4 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Douglas Tsao at HC Wainwright & Co., projecting a 838.3% upside. Conversely, the most conservative target is provided by Ashwani Verma at UBS, suggesting a 40.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CHRS Analyst Ratings
4
Buy
3
Hold
0
Sell
CHRS Price Target Range
Low
$1.05
Average
$6.00
High
$7.00
Current: $0.75
Latest CHRS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CHRS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 29, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $7.00 |
| Apr 24, 2025 | UBS | Ashwani Verma | Neutral | Maintains | $1.05 |
| Mar 11, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $7.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $7.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Dec 5, 2024 | Baird | Colleen Kusy | Outperform | Maintains | $6.00 |
| Dec 4, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $7.00 |
| Nov 8, 2024 | Baird | Colleen Kusy | Outperform | Maintains | $4.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $12.00 |
| Sep 16, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $12.00 |
| Aug 16, 2024 | UBS | Ashwani Verma | Neutral | Downgrade | $1.50 |
| Aug 5, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $12.00 |
| Jul 1, 2024 | Baird | Colleen Kusy | Outperform | Maintains | $8.00 |
| May 24, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $12.00 |
| May 13, 2024 | Truist Securities | Robyn Karnauskas | Buy | Maintains | $7.00 |
| May 10, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $12.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $11.00 |
| Mar 14, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $13.00 |
| Jan 23, 2024 | Baird | Colleen Kusy | Outperform | Maintains | $9.00 |
| Jan 23, 2024 | Truist Securities | Robyn Karnauskas | Buy | Maintains | $8.00 |
Coherus Biosciences Inc. (CHRS) Competitors
The following stocks are similar to Coherus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Coherus Biosciences Inc. (CHRS) Financial Data
Coherus Biosciences Inc. has a market capitalization of $93.91M with a P/E ratio of 1.8x. The company generates $272.25M in trailing twelve-month revenue with a -48.1% profit margin.
Revenue growth is +229.2% quarter-over-quarter, while maintaining an operating margin of -597.9% and return on equity of -21.6%.
Valuation Metrics
Market Cap
$93.91M
Enterprise Value
$301.87M
P/E Ratio
1.8x
PEG Ratio
-3.0x
Price/Sales
0.3x
Growth & Margins
Revenue Growth (YoY)
+229.2%
Gross Margin
+65.1%
Operating Margin
-597.9%
Net Margin
-48.1%
EPS Growth
-90.1%
Financial Health
Cash/Price Ratio
+95.3%
Current Ratio
1.2x
Debt/Equity
-1.6x
ROE
-21.6%
ROA
-9.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Coherus Biosciences Inc. (CHRS) Business Model
About Coherus Biosciences Inc.
What They Do
Develops and commercializes biosimilar products.
Business Model
The company focuses on creating biosimilars, which are cost-effective alternatives to existing biological medicines. By ensuring these products are highly similar to approved therapies, Coherus Biosciences generates revenue through sales to healthcare providers and payers, aiming to improve treatment accessibility while also addressing rising healthcare costs.
Additional Information
Headquartered in Redwood City, California, Coherus was founded in 2010. The company operates in a regulated market and collaborates with various stakeholders, including healthcare providers and patients, to enhance the availability of its products. Its focus areas include oncology, ophthalmology, and immunology, which are critical therapeutic areas in need of affordable treatment options.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
228
CEO
Mr. Dennis M. Lanfear
Country
United States
IPO Year
2014
Website
www.coherus.comCoherus Biosciences Inc. (CHRS) Latest News & Analysis
Latest News
Quick Summary
Coherus BioSciences (NASDAQ:CHRS) will hold its Q1 2025 Earnings Conference Call on May 12, 2025, at 5:00 PM ET, featuring key executives and analysts from various firms.
Why It Matters
Coherus BioSciences' upcoming earnings call may reveal key financial performance and strategic insights, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
1 month ago
Quick Summary
A strategic transformation to oncology was completed in Q2 2025. Positive Phase 1b data for CHS-114 in head and neck cancer was presented. Other trials ongoing; Q1 2025 revenues reported.
Why It Matters
Successful completion of strategic transformation and positive study results in oncology could boost future revenue and stock performance, reflecting growth potential in a competitive market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Coherus BioSciences (CHRS) reported a quarterly loss of $0.35 per share, exceeding the expected loss of $0.31, compared to a loss of $0.32 per share the previous year.
Why It Matters
Coherus BioSciences' larger-than-expected loss signals potential financial instability, which may impact investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Coherus BioSciences (NASDAQ: CHRS) will release Q1 2025 financial results on May 12, 2025, after market close, followed by a conference call at 5:00 p.m. EDT.
Why It Matters
Coherus BioSciences' upcoming financial results and management call could influence stock performance, affecting investor sentiment and trading decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Coherus BioSciences, Inc. (NASDAQ: CHRS) will webcast its participation in upcoming conferences, as announced on May 1, 2025.
Why It Matters
Coherus BioSciences' webcast participation may signal upcoming developments or announcements, affecting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CHS-114 shows clinical efficacy in HNSCC with toripalimab, prompting expansion plans. A Phase 1 study in HNSCC and gastric cancer is ongoing, with results expected by mid-2026.
Why It Matters
CHS-114 shows potential in treating HNSCC and gastric cancer, indicating growth opportunities. Upcoming study results could influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CHRS Stock
What is Coherus Biosciences Inc.'s (CHRS) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Coherus Biosciences Inc. (CHRS) has a median price target of $6.00. The highest price target is $7.00 and the lowest is $1.05.
Is CHRS stock a good investment in 2026?
According to current analyst ratings, CHRS has 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.75. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CHRS stock?
Wall Street analysts predict CHRS stock could reach $6.00 in the next 12 months. This represents a 704.3% increase from the current price of $0.75. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Coherus Biosciences Inc.'s business model?
The company focuses on creating biosimilars, which are cost-effective alternatives to existing biological medicines. By ensuring these products are highly similar to approved therapies, Coherus Biosciences generates revenue through sales to healthcare providers and payers, aiming to improve treatment accessibility while also addressing rising healthcare costs.
What is the highest forecasted price for CHRS Coherus Biosciences Inc.?
The highest price target for CHRS is $7.00 from Douglas Tsao at HC Wainwright & Co., which represents a 838.3% increase from the current price of $0.75.
What is the lowest forecasted price for CHRS Coherus Biosciences Inc.?
The lowest price target for CHRS is $1.05 from Ashwani Verma at UBS, which represents a 40.8% increase from the current price of $0.75.
What is the overall CHRS consensus from analysts for Coherus Biosciences Inc.?
The overall analyst consensus for CHRS is bullish. Out of 10 Wall Street analysts, 4 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are CHRS stock price projections?
Stock price projections, including those for Coherus Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 8, 2025 4:09 AM UTC